You
will certainly not get introduced to me completely, but you can get a
feeling of who I am, what professional views I have and what my
interests are.
Email: peter.v.nagy@gmail.com
The home page of my research group: https://peternagygroup.hu/
I was born and still live in Hungary. I graduated as an M.D. at the University of Debrecen (Hungary) but I was more interested in science even during my university years, so I started to do my PhD in the Department of Biophysics at the same university. I found the combination of quantitative approaches (experimental and analytical), physics and biology very promising. After doing a postdoc at the Department of Molecular Biology at the Max Planck Institute for Biophysical Chemistry (Göttingen, Germany), I returned to my alma mater and currently work as a professor at the Department of Biophysics and Cell Biology, University of Debrecen, Hungary.
A molecular understanding of the details of biological regulation is fascinating. Trying to find a solution to a biological problem is often cumbersome but the challenge keeps my brain awake. So that's one of the things; to satisfy my own interest.At the same time if anyone has ever experienced the suffering of cancer patients (both mental and physical), and the tribulations of those who care for the beloved relative or friend, can and must gather impetus on the seemingly never-ending venture to find a better or to find the best cure for this debilitating disease. Even basic researchers should keep this in mind.
In this paragraph I briefly describe what you can find in more detail in the "Professional interests" tab under "What do I do".I
like to analyze biological problems in a complex way in the hope of
revealing such truths which would remain hidden if conventional methods
are applied. I am interested in breast cancer, in particular in the role
of the epidermal growth factor receptor (EGFR, ErbB or HER) family of
receptor tyrosine kinases.These receptors form homo- and heteroclusters
with different stoichiometries which are rearranged upon ligand binding.
After ligand binding these receptor clusters induce such transmembrane
signaling events which culminate in DNA synthesis, cell division or
cellular motility. All of these features are important for malignant
tumors. Therefore, it's no surprise that ErbB receptors are often
overexpressed in human cancers. Recently we have witnessed the
development of such specific, receptor-oriented therapeuticals which
inhibit the growth of cancer (expressing the targeted protein) without
major side-effects. So my two major interests are